| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Hyun Young Woo | |
| Jeong Heo | |||
| P2860 | cites work | Thunder and lightning: immunotherapy and oncolytic viruses collide | Q24597894 |
| Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197 | Q24608143 | ||
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma | Q28247867 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Hepatocellular carcinoma | Q29616359 | ||
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival | Q29616865 | ||
| Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma | Q29617957 | ||
| Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma | Q30479629 | ||
| Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma | Q46207848 | ||
| Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis | Q47819721 | ||
| Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. | Q50535030 | ||
| Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. | Q51642133 | ||
| Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. | Q53356745 | ||
| Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial | Q58236593 | ||
| Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization | Q71905834 | ||
| Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma | Q79761884 | ||
| Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey | Q80439339 | ||
| Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis | Q81712500 | ||
| The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma | Q83958505 | ||
| Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study | Q85026135 | ||
| Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study | Q86256843 | ||
| Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma | Q87505166 | ||
| A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. | Q33368982 | ||
| Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis | Q33584901 | ||
| Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study | Q33590407 | ||
| Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials | Q34068152 | ||
| Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan | Q34091171 | ||
| Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Q34327051 | ||
| Multicenter validation study of a prognostic index for portal vein tumor thrombosis in hepatocellular carcinoma | Q34386046 | ||
| Chemoembolization for hepatocellular carcinoma | Q34552214 | ||
| Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients | Q34569671 | ||
| Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis | Q34585175 | ||
| Novel advancements in the management of hepatocellular carcinoma in 2008. | Q34588842 | ||
| Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). | Q34617026 | ||
| Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis | Q34659148 | ||
| Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma | Q34743529 | ||
| Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes | Q35004090 | ||
| Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy | Q35086690 | ||
| Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma | Q35116226 | ||
| Hepatocellular carcinoma in Central Europe: prognostic features and survival | Q35362361 | ||
| Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study | Q36230740 | ||
| Partial volume tolerance of the liver to radiation. | Q36267553 | ||
| Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis | Q37359379 | ||
| Hepatocellular carcinoma: A global view. | Q37589349 | ||
| Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. | Q37832895 | ||
| Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib | Q37995993 | ||
| Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?. | Q38083434 | ||
| Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. | Q38101443 | ||
| Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. | Q38122306 | ||
| Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design | Q38192888 | ||
| Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. | Q39246920 | ||
| Liver resection after downstaging hepatocellular carcinoma with sorafenib | Q39446538 | ||
| Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia | Q42615624 | ||
| Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib | Q43124491 | ||
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial | Q43522867 | ||
| Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. | Q43817879 | ||
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial | Q44089673 | ||
| Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis | Q44347050 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| venous thrombosis | Q2751330 | ||
| liver neoplasm | Q18558073 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 115-121 | |
| P577 | publication date | 2015-06-01 | |
| 2015-06-26 | |||
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis | |
| P478 | volume | 21 |
| Q33872982 | A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function |
| Q33438161 | Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a meta-analysis |
| Q59203660 | Comparison of three-dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus |
| Q91673617 | Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria |
| Q41226032 | Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis |
| Q36325065 | Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data |
| Q33750002 | High-biologically effective dose palliative radiotherapy for a tumor thrombus might improve the long-term prognosis of hepatocellular carcinoma: a retrospective study |
| Q92645713 | Interleukin-6 as a biomarker in patients with hepatobiliary cancers |
| Q90012573 | Macrovascular Endothelial Cells Enhance the Motility of Liver Cancer Cells by Up-regulation of MMP-3, Activation of Integrin/FAK Signaling Pathway and Induction of Non-classical Epithelial-mesenchymal Transition |
| Q64987573 | Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion. |
| Q47127377 | Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. |
| Q39754560 | Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma |
| Q50957095 | Prognostic factors of hepatocellular carcinoma patients with portal vein tumor thrombosis treated with transcatheter arterial chemoembolization. |
| Q36009432 | Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. |
| Q50795926 | Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. |
| Q88310077 | Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial |
| Q38708569 | Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. |
| Q49332642 | Tumor thrombus: incidence, imaging, prognosis and treatment |
Search more.